Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial

NCT04245514 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT04245514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04245514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 15, 2020
Completion date
December 31, 2031
Enrollment
90 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, nsclc